Compare DexCom, Inc. (DXCM) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Nasdaq Inc — how do they compare? DexCom, Inc. trades at $77.3 (market cap $28.06B), while Nasdaq Inc trades at $94.49 (market cap $51.67B). The key difference: Nasdaq Inc is the larger of the two by market cap, and Nasdaq Inc pays a 1.23% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | NDAQ | |
|---|---|---|
Market Cap | $28.06B | $51.67B |
Sector | Health | Financials |
52-Week High | $89.53 | $100.98 |
52-Week Low | $54.84 | $76.85 |
Enterprise Value | $27.03B | $58.73B |
Dividend Yield | — | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Nasdaq (NDAQ) trades at $94.72, up 7.62% with strong bullish momentum. The stock shows robust fundamentals with revenue growth to $8.26B in 2025 and net income margin of 23.03%. Recent earnings beats and a $0.31 dividend signal financial health. Technical indicators show overbought conditions but overall bullish sentiment.
Outlook remains positive with analyst consensus target of $105.60, though risks include market volatility and high valuation multiples. Investment opportunity lies in continued earnings growth and strategic positioning as a leading exchange operator.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
